Photo by nci from unsplash
Development of inhibitors is the most serious complication in patients with haemophilia (PWH). The prevalence of inhibitors in patients with severe haemophilia A (HA) is approximately 25%‐30%. Inhibitor prevalence differs… Click to show full abstract
Development of inhibitors is the most serious complication in patients with haemophilia (PWH). The prevalence of inhibitors in patients with severe haemophilia A (HA) is approximately 25%‐30%. Inhibitor prevalence differs among populations. Some studies report a prevalence of almost twice in Hispanic as compared to Caucasian patients. Most data available, on the prevalence of inhibitors and their predisposing factors, originate from centres in developed countries.
Keywords:
prevalence inhibitors;
patients haemophilia;
characteristics patients;
prevalence;
inhibitors clinical;
clinical characteristics
Journal Title: Haemophilia
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!